US Patent

US8741881 — Testosterone gel and method of use

Method of Use · Assigned to Besins Healthcare Luxembourg SARL · Expires 2026-10-12 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an improved transdermal hydroalcoholic testosterone gel formulation and its methods of use.

USPTO Abstract

The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.

Drugs covered by this patent

Androgel (TESTOSTERONE) · Besins Hlthcare

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1103`	—	Androgel
`U-1103`	—	Androgel
`U-1103`	—	Androgel

Patent Metadata

Patent number: US8741881
Jurisdiction: US
Classification: Method of Use
Expires: 2026-10-12
Drug substance claim: No
Drug product claim: No
Assignee: Besins Healthcare Luxembourg SARL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.